Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM2 | P50570 | 11/20 | 0.62 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | RAC1 | P63000 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15360223 | 0.83 | DNM2 (0.66) | DNM2NCF1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11464694 | 0.78 | DNM2 (0.58) | DNM2NCF1TP53HRH3CYP2C19 | |
| SCHEMBL16608839 | 0.77 | LMNA (0.46) | SMN1; SMN2ALDH1A1LMNAMAPK1HTT | |
| SCHEMBL25474229 | 0.76 | DNM2 (1.00) | DNM2SMN1; SMN2ALDH1A1LMNATP53 | |
| SCHEMBL30481105 | 0.76 | DNM2 (0.57) | DNM2NCF1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11462337 | 0.76 | DNM2 (0.63) | DNM2NCF1MAPK1 | |
| SCHEMBL11187910 | 0.74 | DNM2 (0.55) | DNM2NCF1ALDH1A1TP53HRH3 | |
| SCHEMBL12411159 | 0.74 | NOS3 (0.48) | ALDH1A1LMNAMAPK1HTTCYP2C19 | |
| SCHEMBL12410776 | 0.73 | LMNA (0.52) | ALDH1A1LMNAMAPK1HTTCYP2C19 | |
| SCHEMBL12411153 | 0.73 | TAAR1 (0.54) | DNM2ALDH1A1LMNATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | DNM2 465/4885NCF1 1917/4885RAC1 2084/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | DNM2 465/4885NCF1 1917/4885RAC1 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.